A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

Explore how political divisiveness impacts mental health and amplifies high-functioning depression, and discover strategies ...

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.

A compelling new study is building on a growing body of evidence showing a common exercise supplement used to build muscle ...

NeuroStar is committed to advancing the body of scientific research and elevating mental health treatment through robust research and data-driven innovation,” stated Keith J. Sullivan, President and ...

(HealthDay News) — Preventive psychological interventions may be effective for adults with subthreshold depressive symptoms, according to a review published online in the December issue of The Lancet ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few years now.

A new study from the Texas A&M University School of Public Health provides additional evidence that meditation using ...

Neurocrine Biosciences advances Phase 3 plans for osavampator after achieving Phase 2 success in major depressive disorder, amending its Takeda deal.

Takeda is taking back the home license for a phase 3-stage depression drug as part of an amendment to its multi-asset ...